Search results
Showing 301 to 315 of 729 results for innovative
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Biographies and registered interests for members of the Technology Appraisal Committee C
Biographies and registered interests for members of the Technology Appraisal Committee C
Curos for preventing infections when using needleless connectors (HTG510)
Evidence-based recommendations on Curos for preventing infections when using needleless connectors.
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .
SimpliCT laser-guided needle placement in interventional radiology (MIB98)
NICE has developed a medtech innovation briefing (MIB) on SimpliCT laser-guided needle placement in interventional radiology .
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)
NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
Evidence-based recommendations on tebentafusp (Kimmtrak) for treating uveal melanoma in adults.
Show all sections
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.